IPSEN BIOPHARM LTD
BiotechIPSEN BIOPHARM LTD is a biotechnology company focused on Oncology, Neurology, Gastroenterology.
IPSEN BIOPHARM LTD at a Glance
- Leading 5 drug targets across portfolio
- Fast trial execution (28 months median completion)
IPSEN BIOPHARM LTD's Key Drugs
IPSEN BIOPHARM LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
IPSEN BIOPHARM LTD's Recent FDA Approvals
New NDA/BLA approvals for IPSEN BIOPHARM LTD over the last two years — novel drugs only, excluding generics and label supplements.
IPSEN BIOPHARM LTD's Therapeutic Areas
IPSEN BIOPHARM LTD's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Neurology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IPSEN BIOPHARM LTD's Top Competitors
IPSEN BIOPHARM LTD's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and EMD SERONO. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IPSEN BIOPHARM LTD Pipeline Snapshot
IPSEN BIOPHARM LTD has 49 active clinical programs from ClinicalTrials.gov — 12 Phase 3, 19 Phase 2 and 18 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 32/47 completed
- • Speed: 28 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2009-04-29
- Latest
- 2023-09-21
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges